A randomised factorial trial of sequential doxorubicin and CMF vs CMF and chemotherapy alone vs chemotherapy followed by goserelin plus tamoxifen as adjuvant treatment of node-positive breast cancer

@article{Placido2005ARF,
  title={A randomised factorial trial of sequential doxorubicin and CMF vs CMF and chemotherapy alone vs chemotherapy followed by goserelin plus tamoxifen as adjuvant treatment of node-positive breast cancer},
  author={Sabino de Placido and Michelino de Laurentiis and Mario De Lena and Vito Lorusso and Angelo Paradiso and Modesto D'Aprile and Giorgio Pistillucci and Alessandro Farris and Maria Giuseppa Sarobba and Stefano Palazzo and Luigi Manzione and Vincenzo Adamo and Sebastian T. Palmeri and Francesco Ferra{\`u} and Rossella Lauria and Clorindo Pagliarulo and Giuseppe Petrella and Gennaro Limite and Roberta Costanzo and Angelo Raffaele Bianco},
  journal={British Journal of Cancer},
  year={2005},
  volume={92},
  pages={467 - 474}
}
The sequential doxorubicin → CMF (CMF=cyclophosphamide, methotrexate, fluorouracil) regimen has never been compared to CMF in a randomised trial. The role of adding goserelin and tamoxifen after chemotherapy is unclear. In all, 466 premenopausal node-positive patients were randomised to: (a) CMF × 6 cycles (CMF); (b) doxorubicin × 4 cycles followed by CMF… CONTINUE READING